Alnylam Pharmaceuticals Inc (ALNY)
NASDAQ · Healthcare
Alnylam Pharmaceuticals Inc EBITDA 2008–2025
Alnylam Pharmaceuticals Inc annual/quarterly ebitda history and growth rate from 2008 to 2025. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Alnylam Pharmaceuticals Inc ebitda for the quarter ending March 31, 2025 was 32.5 M, a 208.57% decrease year-over-year.
- Alnylam Pharmaceuticals Inc ebitda for the twelve months ending March 31, 2025 was -270.4 M, a 61.66% decrease year-over-year.
- Alnylam Pharmaceuticals Inc annual ebitda for 2025 was 557.2 M, a 563.53% decrease from 2024.
- Alnylam Pharmaceuticals Inc annual ebitda for 2024 was -120.2 M, a 47.30% decrease from 2023.
- Alnylam Pharmaceuticals Inc annual ebitda for 2023 was -228.1 M, a 69.20% decrease from 2022.
- Alnylam Pharmaceuticals Inc annual ebitda for 2022 was -740.6 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Alnylam Pharmaceuticals Inc EBITDA — FAQ
Alnylam Pharmaceuticals Inc (ALNY) ebitda over the last 13 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see ALNY's ebitda history?
The chart and table above show Alnylam Pharmaceuticals Inc's ebitda by year and by quarter, including the growth rate.